Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- 7 Japan Major Drug Makers See Limited Impact from COVID-19: FY2019 Earnings
May 18, 2020
- Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
- Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
- Takeda’s Adcetris Gets EU OK for 1st-Line sALCL Treatment in Combo with Chemo
May 18, 2020
- Chugai Licenses Antibody Engineering Technologies to Lilly in COVID-19 Pact
May 18, 2020
- JT Files Riona for Iron Deficiency Anemia in Japan
May 18, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Ono Files Opdivo for 1st-Line Treatment for Unresectable Advanced/Recurrent Gastric Cancer
May 15, 2020
- Sumitomo Dainippon to Upscale Digital Info Provisioning, Face-to-Face Approach also Important: President
May 15, 2020
- Astellas Taking Flexible Approaches towards Patients Enrolled in Clinical Studies amid COVID-19 Pandemic
May 15, 2020
- Denka to Start Production of Raw Material for Avigan from May 16
May 15, 2020
- Eisai Resurrects Eritoran as Potential COVID-19 Treatment, Eyes Trial Launch Next Month
May 14, 2020
- Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
- Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
May 14, 2020
- Eisai Chalks Up Record Profits on Lenvima Boon
May 14, 2020
- Ono to Establish Subsidiary in US to Manage New Venture Investment Fund
May 14, 2020
- Nippon Shinyaku Starts Enrolling Patients in Multinational PIII of Viltolarsen
May 14, 2020
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Sumitomo Dainippon’s FY2019 Sales Up 5.1% on Equa/EquMet Addition
May 14, 2020
- Roche Diagnostics Rolls Out Coronavirus Antibody Detection Reagents in Japan
May 14, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…